Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $26,032.50 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Yeu Lin sold 375 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $69.42, for a total value of $26,032.50. Following the completion of the sale, the insider owned 24,077 shares of the company’s stock, valued at $1,671,425.34. The trade was a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Thursday, March 19th, Elizabeth Yeu Lin sold 390 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $67.00, for a total value of $26,130.00.
• On Wednesday, March 18th, Elizabeth Yeu Lin sold 379 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $68.71, for a total value of $26,041.09.

Tarsus Pharmaceuticals Trading Down 3.4%

NASDAQ TARS opened at $64.51 on Friday. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -39.82 and a beta of 0.55. The company’s 50-day simple moving average is $69.12 and its two-hundred day simple moving average is $70.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Tarsus Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after purchasing an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Tarsus Pharmaceuticals by 2.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after buying an additional 1,394 shares during the last quarter. Jane Street Group LLC boosted its position in Tarsus Pharmaceuticals by 105.8% in the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after buying an additional 190,000 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in Tarsus Pharmaceuticals by 15.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock worth $420,000 after buying an additional 1,418 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Tarsus Pharmaceuticals by 8.0% in the 2nd quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock worth $37,859,000 after buying an additional 68,986 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Analysts Set New Price Targets

TARS has been the subject of a number of analyst reports. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Lifesci Capital raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Guggenheim upped their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.83.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.